CorrespondenceDelayed allergic reactions to omalizumab: Are patients reporting all cases?
Reference (1)
- et al.
Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma
J Allergy Clin Immunol
(2007)
Cited by (9)
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report
2011, Journal of Allergy and Clinical ImmunologyOmalizumab-associated anaphylactic reactions reported between January 2007 and June 2008
2009, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :The calculated prevalence of these reactions of approximately 0.2% was higher than expected on the basis of clinical trial data,7 where a 0.1% prevalence was noted. Furthermore, they showed that omalizumab-associated anaphylaxis may have delayed onset in some cases, which can obscure identification of the cause of the anaphylaxis.8 There also may be underreporting of allergic reactions to omalizumab due to the fear of not being able to continue treatment deemed effective by the patient.
Advances in adult asthma diagnosis and treatment and health outcomes, education, delivery, and quality in 2008
2009, Journal of Allergy and Clinical ImmunologyCitation Excerpt :In 2007, Limb et al76 reported a series of 124 cases of anaphylaxis attributed to omalizumab, characterized by delayed onset and protracted progression of symptoms. A similar event was reported this year by Barry et al.77 As Limb et al78 note, only 1% to 10% of all adverse events are ever reported, so it is possible other omalizumab events are unreported. As electronic medical records and web-based reporting systems are more widely used, adverse drug reactions can be better studied.79
Reply
2008, Journal of Allergy and Clinical ImmunologyAsthma that is unresponsive to usual care
2010, CMAJ. Canadian Medical Association JournalAdverse reaction to omalizumab in patients with chronic urticaria: Flare up or ineffectiveness?
2016, Iranian Journal of Allergy, Asthma and Immunology
Disclosure of potential conflict of interest: T. M. O'Connor has received research support from AstraZeneca. The rest of the authors have declared that they have no conflict of interest.